Grifols, S.A. (NASDAQ:GRFS) Short Interest Down 10.8% in November

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 3,720,000 shares, a drop of 10.8% from the October 31st total of 4,170,000 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 950,500 shares, the days-to-cover ratio is presently 3.9 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GRFS. Tidal Investments LLC bought a new stake in shares of Grifols during the third quarter worth $147,000. Sanctuary Advisors LLC bought a new stake in shares of Grifols during the third quarter valued at approximately $312,000. Geode Capital Management LLC grew its stake in Grifols by 56.1% in the third quarter. Geode Capital Management LLC now owns 110,532 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 39,733 shares in the last quarter. Barclays PLC increased its holdings in Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 469,401 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of Grifols in the 3rd quarter worth $363,000.

Grifols Trading Up 2.0 %

NASDAQ:GRFS traded up $0.14 during trading hours on Tuesday, reaching $7.13. The stock had a trading volume of 2,535,740 shares, compared to its average volume of 1,309,563. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols has a 52 week low of $5.30 and a 52 week high of $12.15. The company has a 50 day moving average price of $8.76 and a two-hundred day moving average price of $8.11.

Wall Street Analyst Weigh In

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.